Atrial natriuretic peptide ameliorates peritoneal fibrosis in rat peritonitis model

Nephrology Dialysis Transplantation

Volumn 27, Issue 2, 2012, Pages 526-536

  Kato, Hiroshi ^a,b   Mizuno, Tomohiro ^a,b   Mizuno, Masashi ^c   Sawai, Akiho ^c   Suzuki, Yasuhiro ^c   Kinashi, Hiroshi ^c   Nagura, Fumiko ^c   Maruyama, Shoichi ^c   Noda, Yukihiro ^a   Yamada, Kiyofumi ^b   Matsuo, Seiichi ^c   Ito, Yasuhiko ^c  

^a MEIJO UNIVERSITY   (Japan)

^b Hospital Pharmacy   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

ANP; CTGF; peritoneal fibrosis; renin angiotensin system; TGF

Indexed keywords

ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR RECEPTOR; CD31 ANTIGEN; COLLAGEN TYPE 3; CONNECTIVE TISSUE GROWTH FACTOR; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; SODIUM CHLORIDE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FIBROBLAST; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MESOTHELIUM CELL; NONHUMAN; OSMOTIC PUMP; PERITONEAL FIBROSIS; PERITONITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ANALYSIS OF VARIANCE; ANIMALS; ATRIAL NATRIURETIC FACTOR; BIOPSY, NEEDLE; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FIBROBLASTS; IMMUNOHISTOCHEMISTRY; INFUSIONS, INTRAVENOUS; MALE; PERITONEAL FIBROSIS; PERITONEUM; PERITONITIS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ATRIAL NATRIURETIC FACTOR; REFERENCE VALUES; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC;

EID: 84856816828     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfr302     Document Type: Article

References (52)

1. Williams JD, Craig KJ, Topley N et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13: 470-479
2. Kawaguchi Y, Ishizaki T, Imada A et al. Searching for the reasons for drop-out from peritoneal dialysis: a nationwide survey in Japan. Perit Dial Int 2003; 23: S175-S177
3. Nakayama M. Fluid status and its management in Japanese peritoneal dialysis patients. Perit Dial Int 2006; 26: 144-149
4. Ota K, Mineshima M, Watanabe N et al. Functional deterioration of the peritoneum: does it occur in the absence of peritonitis? Nephrol Dial Transplant 1987; 2: 30-33
5. Selgas R, Fernandez-Reyes MJ, Bosque E et al. Functional longevity of the human peritoneum: how long is continuous peritoneal dialysis possible? Results of a prospective medium long-term study. Am J Kidney Dis 1994; 23: 64-73
6. Davies SJ, Bryan J, Phillips L et al. Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 1996; 11: 498-506
7. Di Paolo N, Sacchi G. Atlas of peritoneal histology. Perit Dial Int 2000; 20: S5-S96
8. Henderson IS, Dobbie JW, Zaki MA et al. Structure of peritoneum and changes brought about by infection. Contrib Nephrol 1987; 57: 30-40
9. Rubin J, Herrera GA, Collins D. An autopsy study of the peritoneal cavity from patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1991; 18: 97-102
10. Ersoy R, Celik A, Yilmaz O et al. The effects of irbesartan and spironolactone in prevention of peritoneal fibrosis in rats. Perit Dial Int 2007; 27: 424-431
11. Nessim SJ, Perl J, Bargman JM. The renin-angiotensin-aldosterone system in peritoneal dialysis: is what is good for the kidney also good for the peritoneum? Kidney Int 2010; 78: 23-28
12. Nishimura H, Ito Y, Mizuno M et al. Mineralocorticoid receptor blockade ameliorates peritoneal fibrosis in new rat peritonitis model. Am J Physiol Renal Physiol 2008; 294: 1084-1093
13. Xie J, Wu K, Wang W et al. Role of angiotensin II in peritoneal fibrosis and its related signal pathways. J Am Soc Nephrol 2006; 17: 756A
14. Miyazaki M, Yuzawa Y. The role of peritoneal fibrosis in encapsulating peritoneal sclerosis. Perit Dial Int 2005; 25: S48-S56
15. Sawada T, Ishii Y, Tojimbara T et al. The ACE inhibitor, quinapril, ameliorates peritoneal fibrosis in an encapsulating peritoneal sclerosis model in mice. Pharmacol Res 2002; 46: 505-510
16. Suzuki H, Kanno Y, Sugahara S et al. Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis 2004; 43: 1056-1064
17. Patel JB, Valencik ML, Pritchett AM et al. Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload. Am J Physiol Heart Circ Physiol 2005; 289: H777-H784
18. Nishikimi T, Maeda N, Matsuoka H. The role of natriuretic peptides in cardioprotection. Cardiovasc Res 2006; 69: 318-328
19. Lin X, Hänze J, Heese F et al. Gene expression of natriuretic peptide receptors in myocardial cells. Circ Res 1995; 77: 750-758
20. Glenn DJ, Rahmutula D, Nishimoto M et al. Atrial natriuretic peptide suppresses endothelin gene expression and proliferation in cardiac fibroblasts through a GATA4-dependent mechanism. Cardiovasc Res 2009; 84: 209-217
21. Nishikimi T, Hagaman JR, Takahashi N et al. Increased susceptibility to heart failure in response to volume overload in mice lacking natriuretic peptide receptor-A gene. Cardiovasc Res 2005; 66: 94-103
22. Oliver PM, Fox JE, Kim R et al. Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A. Proc Natl Acad Sci 1997; 94: 14730-14735
23. Tamura N, Ogawa Y, Chusho H et al. Cardiac fibrosis in mice lacking brain natriuretic peptide. Proc Natl Acad Sci 2000; 97: 4239-4244
24. Franco V, Chen YF, Oparil S et al. Atrial natriuretic peptide dosedependently inhibits pressure overload-induced cardiac remodeling. Hypertension 2004; 44: 746-750
25. Mori T, Chen YF, Feng JA et al. Volume overload results in exaggerated cardiac hypertrophy in the atrial natriuretic peptide knockout mouse. Cardiovasc Res 2004; 61: 771-779
26. Holtwick R, van Eickels M, Skryabin BV et al. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest 2003; 111: 1399-1407
27. Maki T, Horio T, Yoshihara F et al. Effect of neutral endopeptidase inhibitor on endogenous atrial natriuretic peptide as a paracrine factor in cultured cardiac fibroblasts. Br J Pharmacol 2000; 131: 1204-1210
28. Cao L, Gardner DG. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension 1995; 25: 227-234
29. Kasama S, Furuya M, Toyama T et al. Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction. Eur Heart J 2008; 29: 1485-1494
30. Tsuneyoshi H, Nishina T, Nomoto T et al. Atrial natriuretic peptide helps prevent late remodeling after left ventricular aneurysm repair. Circulation 2004; 110 (11 Suppl I): II-174-II-179
31. Ito Y, Goldschmeding R, Bende R et al. Kinetics of connective tissue growth factor expression during experimental proliferative glomerulonephritis. J Am Soc Nephrol 2001; 12: 472-484
32. Ito Y, Aten J, Bende RJ et al. Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 1998; 53: 853-861
33. Kawai H, Sato W, Yuzawa Y et al. Lack of the growth factor midkine enhances survival against cisplatin-induced renal damage. Am J Pathol 2004; 165: 1603-1612
34. Witowski J, Jörres A. Peritoneal cell culture: fibroblasts. Perit Dial Int 2006; 26: 292-299
35. Mizuno T, Mizuno M, Morgan BP et al. Specific collaboration between rat membrane complement regulators Crry and CD59 protects peritoneum from damage by autologous complement activation. Nephrol Dial Transplant 2011; 26: 1821-1830
36. Fujisaki H, Ito H, Hirata Y et al. Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest 1995; 96: 1059-1065
37. Lara-Castillo N, Zandi S, Nakao S et al. Atrial natriuretic peptide reduces vascular leakage and choroidal neovascularization. Am J Pathol 2009; 175: 2343-2350
38. Mizutani M, Ito Y, Mizuno M et al. Connective tissue growth factor (CTGF/CCN2) is increased in peritoneal dialysis patients with high peritoneal solute transport rate. Am J Physiol Renal Physiol 2010; 298: F721-F733
39. Hayashi M, Tsutamoto T, Wada A et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2001; 37: 1820-1826
40. Hayashi Y, Ohtani M, Hiraishi T et al. Synthetic human alpha-atrial natriuretic peptide infusion in management after open heart operations. ASAIO J 2003; 49: 320-324
41. Kasahara M, Mukoyama M, Sugawara A et al. Ameliorated glomerular injury in mice overexpressing brain natriuretic peptide with renal ablation. J Am Soc Nephrol 2000; 11: 1691-1701
42. Makino H, Mukoyama M, Mori K et al. Transgenic overexpression of brain natriuretic peptide prevents the progression of diabetic nephropathy in mice. Diabetologia 2006; 49: 2514-2524
43. Bellingan GJ, Caldwell H, Howie SE et al. In vivo fate of the inflammatory macrophage during the resolution of inflammation: inflammatory macrophages do not die locally, but emigrate to the draining lymph nodes. J Immunol 1996; 157: 2577-2585
44. Lai KN, Lai KB, Lam CWK et al. Changes of cytokine profiles during peritonitis in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 2000; 35: 644-652
45. Topley N, Liberek T, Davenport A et al. Activation of inflammation and leukocyte recruitment into the peritoneal cavity. Kidney Int 1996; 56: S17-S21
46. Hurst SM, Wilkinson TS, McLoughlin RM et al. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001; 14: 705-714
47. Kiribayashi K, Masaki T, Naito T et al. Angiotensin II induces fibronectin expression in human peritoneal mesothelial cells via ERK1/2 and p38 MAPK. Kidney Int 2005; 67: 1126-1135
48. Noh H, Ha H, Yu MR et al. Angiotensin II mediates high glucoseinduced TGF-beta1 and fibronectin upregulation in HPMC through reactive oxygen species. Perit Dial Int 2005; 25: 38-47
49. Rupérez M, Lorenzo O, Blanco-Colio LM et al. Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation 2003; 108: 1499-1505
50. Rupérez M, Ruiz-Ortega M, Esteban V et al. Angiotensin II increases connective tissue growth factor in the kidney. Am J Pathol 2003; 163: 1937-1947
51. Kiemer AK, Vollmar AM. The atrial natriuretic peptide regulates the production of inflammatory mediators in macrophages. Ann Rheum Dis 2001; 60: iii68-iii70
52. Kitakaze M, Asakura M, Kim J et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 2007; 370: 1483-1493